A distinct coagulopathy associated with interleukin-2 therapy

Br J Haematol. 1994 Dec;88(4):892-4. doi: 10.1111/j.1365-2141.1994.tb05135.x.

Abstract

We studied the coagulation profiles of 14 patients with advanced malignancies treated with Interleukin-2 (IL-2). A 43% prolongation of the PTT (P < 0.001) and a significant decrease in functional levels of factors II, IX, X, XI, and XII were observed 6 h post IL-2 treatment in comparison to pretreatment values. These parameters normalized within 2-3 d following IL-2 administration. The PT, factors V, VII, VIII, fibrinogen and D-dimer levels were unchanged with IL-2 treatment. This pattern of coagulopathy has not previously been reported.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Blood Coagulation Disorders / etiology*
  • Blood Coagulation Factors / analysis
  • Humans
  • Interleukin-2 / adverse effects*
  • Interleukin-2 / therapeutic use
  • Neoplasms / blood
  • Neoplasms / therapy
  • Partial Thromboplastin Time
  • Prospective Studies

Substances

  • Blood Coagulation Factors
  • Interleukin-2